Jefferies Financial Group Inc. Invests $251,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

Jefferies Financial Group Inc. bought a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 20,806 shares of the company's stock, valued at approximately $251,000. Jefferies Financial Group Inc. owned 0.07% of Delcath Systems at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP bought a new position in Delcath Systems in the 4th quarter worth about $34,000. Quantbot Technologies LP purchased a new position in shares of Delcath Systems during the fourth quarter worth about $66,000. Boothbay Fund Management LLC increased its position in shares of Delcath Systems by 30.2% in the fourth quarter. Boothbay Fund Management LLC now owns 34,749 shares of the company's stock worth $418,000 after purchasing an additional 8,061 shares during the last quarter. Riverwater Partners LLC increased its position in shares of Delcath Systems by 46.2% in the fourth quarter. Riverwater Partners LLC now owns 27,229 shares of the company's stock worth $328,000 after purchasing an additional 8,601 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in Delcath Systems in the fourth quarter valued at approximately $123,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Trading Down 0.2%

DCTH traded down $0.04 during midday trading on Friday, reaching $16.11. The company's stock had a trading volume of 551,896 shares, compared to its average volume of 371,106. Delcath Systems, Inc. has a 1 year low of $6.33 and a 1 year high of $18.23. The firm has a market capitalization of $561.05 million, a price-to-earnings ratio of -11.93 and a beta of 0.72. The stock's 50-day moving average is $13.05 and its 200-day moving average is $12.96.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.07). The business had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. As a group, equities research analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price target on Delcath Systems from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $24.00.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.